Summary Amplification and expression of the mdrl gene encoding P-glycoprotein have been studied in H69/LX4 a multidrug resistant variant (MDR) of small cell lung cancer (SCLC) cell line NCI-H69. Recently a second independently derived MDR variant of this cell line designated H69/AR was found by others not to show amplification, rearrangement or over-expression of the mdrl gene. The present study reports that in marked contrast to H69/AR, H69/LX4 shows amplification and expression of the P-glycoprotein gene and raises the possibility that P-glycoprotein hyperexpression may be a clinically relevant component of MDR in some SCLC tumours.
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Resistance of tumours to multiple drugs is a major problem in cancer treatment. Studies using in vitro derived multidrugresistant (MDR) cell lines have shown that MDR is often associated with over-production of two groups of proteins: the P-glycoproteins (for review see which have drug-binding properties (Safa et al., 1986) and are thought to function as a membrane anchored efflux pump for multiple drugs (Willingham et al., 1986) ; and sorcin/CP22 (Meyers et al., 1985; Meyers & Biedler, 1981; Koch et al., 1986; Martinnson et al., 1985; Shen et al., 1986a ; Van der Bliek et al., 1986a) , a small cytosolic calcium-binding protein. Considerable evidence supports the hypothesis that it is P-glycoprotein that is responsible for MDR in almost all cell lines examined (Debenham et al., 1982; Gros et al., 1986; Kartner et al., 1983; Robertson et al., 1984; Scotto et al., 1986; Shen et al., 1986b; Van der Bliek et al., 1986b) .
In an effort to elucidate mechanisms of MDR in human small cell lung cancer (SCLC), multidrug resistant variants (MDR) of human SCLC cell line NCI-H69, have recently been derived following cell culture in increasing doses of adriamycin (ADM) Mirksi et al., 1987) . Surprisingly, the MDR variant H69/AR (Mirski et al., 1987) does not show amplification, rearrangement or overexpression of the P-glycoprotein gene (Trent et al., 1988) suggesting that other factors are responsible for the MDR phenotype in these cells. The present study investigates Pglycoprotein gene amplification and expression in H69/LX4 a second, independently derived MDR variant of NCI-H69. We report that, in marked contrast to H69/AR cells, amplification and hyperexpression of P-glycoprotein gene occurs in this MDR cell line.
Materials and methods

Cell lines
The SCLC cell line NCI-H69 (kindly supplied by Drs Desmond Carney and Adi Gazdar of the NCI Navy Medical Oncology Branch, Bethesda, MD) was derived from a patient who had previously received multidrug therapy (including ADM).
Full details of the in vitro derivation of the MDR variant of NCI-H69 are given elsewhere ).
H69P and LX4 were maintained in RPMI 1640 medium supplemented with 10% fetal calf serum, penicillin and streptomycin (all Gibco Europe Ltd).
The adenosine-, thymidine-and glycine-requiring auxotroph AUXB1 of Chinese hamster ovary (CHO) cells and its colchicine-resistant mutant CH'CS (Juliano & Ling, 1976) were kindly supplied by Dr Victor Ling of the Ontario Cancer Institute, Toronto, Canada.
Antibodies to P-glycoprotein
The mouse monoclonal antibody C219 which recognises a highly conserved determinant of P-glycoprotein was generously donated by Dr Victor Ling.
cDNA probes The mdrl-specific cDNA probe (pHDR105) (Roninson et al., 1986) was generously donated by Dr Igor Roninson (Center for Genetics, University of Illinois College of Medicine at Chicago, Chicago). Identification of mdrl as a human P-glycoprotein gene has been confirmed by crosshybridisation between P-glycoprotein and mdrl cDNA clones (Ueda et al., 1986) .
Preparation of plasma membrane fractions
The isolation of plasma membranes was accomplished as previously described (Riordan & Ling, 1979) . Briefly, cells were disrupted using a Stansted cell disruptor at a pressure of 30p.s.i. for H69P and 20p.s.i. for LX4 cells. Following differential centrifugation (Riordan & Ling, 1979 ) the microsomal pellets were applied to a discontinuous sucrose gradient consisting of 60% (w/v), 45%, 31% and 16%. sucrose, and centrifuged at 76,900g for 18 h. Material banding at the three interfaces was collected and solubilised in 0.1 % sodium dodecyl sulphate (SDS). Protein determinations were carried out using a BCA protein assay kit (Pierce (UK) Ltd, Cambridge, UK).
Immunoblotting For the immunodetection of P-glycoprotein, microsomal membrane proteins were subjected to SDS-gel electrophoresis (Debenham et al., 1982) . Transfer of resolved proteins from gels to nitrocellulose filter paper was as described by Towbin et al. (1979) . Protein transfer was performed for 4 h at 4°C at a constant current of 0.5 A using a solution containing 0.0125M Tris, 0.2M glycine (pH 8.5) and 20% methanol as the electrode buffer. After transfer, additional protein binding sites on nitrocellulose were blocked by incubation of the paper overnight in 5mM EDTA, 0.25% gelatin, 0.01 M NaN3, 0.15M NaCl, 0.05M Tris-base, and 0.05% Nonidet P40 (NGA buffer). The paper was then incubated overnight at 4°C with MoAb C219 diluted in NGA buffer. After washing, 125I-labelled rabbit anti-mouse Ig was used to visualise MoAb C219 binding. RNA preparation Cells in logarithmic phase of growth were collected by centrifugation at 300g for 10min and suspended in 100l, of medium. A solution containing 6.0 M guanidine hydrochloride and 0.2M sodium acetate (pH 5.5) was added to the cells (20 ml per 5 x 107 cells) and the DNA was sheared by vigorous homogenisation in a Virtis homogeniser (Virtis Company, New York). RNA was precipitated by the addition of a half volume of 95% ethanol followed by incubation at -20°C overnight. The pelleted precipitate was dissolved in a solution containing 7.0M urea, 0.35M NaCI, 50mM Tris, pH 7.5, 1 mM EDTA and 0.2% SDS and was extracted once with phenol-chloroform. RNA was precipitated from the aqueous phase using 2 volumes of ethanol, washed with 70% ethanol, air dried and dissolved in sterile double distilled water.
Agarose gel electrophoresis Twenty micrograms of total cellular RNA in 10mM sodium phosphate buffer (pH 7.0) was denatured in 1.0 M glyoxal for 1 h at 50°C (Thomas, 1980) . The RNA was then electrophoresed in a 1.4% agarose gel in 10mM sodium phosphate buffer and was transferred by Northern blotting to nylon filters (Thomas, 1980) . After treatment for 2 min with ultraviolet light, the nylon filters were baked at 80°C for 2 h before hybridisation.
Preparation of radiolabelled probes
The mdrl cDNA probe was prepared by oligo-labelling (Feinberg et al., 1984) . The 2kb EcoRl fragment cloned into the plasmid pHDR105 was separated from the vector by agarose gel electrophoresis. The 2kb EcoRl fragment, still in the gel slice, was radiolabelled by transcribing the fragment using mixed oligonucleotides to initiate transcription. The radiolabelled probe was separated from unincorporated nucleotide triphosphates using Sephadex G50 (Pharmacia Inc, Piscataway, NJ) and boiled for 3 min before use. A mouse ,B actin probe (PRT3) (kindly donated by Dr John Rogers, Laboratory of Molecular Biology, Cambridge, UK) was labelled by nick-translation (Rigby et al., 1977) .
Hybridisation
The labelled probe, at a concentration of 106 counts min-1 ml-1, was hybridised to the filter in 1 M NaCl, 0.1 M trisodium citrate (6 x SSC), 5% dextran sulphate, 0.02% Ficoll, 0.02% bovine serum albumen, 0.02% polyvinyl pyrrolidone (Denhardt, 1966) , 0.1% SDS and 150 pg ml -1 sonicated salmon sperm DNA at 65°C for 18 h. The filter was washed with 6 x SSC, 0.1% SDS at 65°C to remove unhybridised probe autoradiography.
DNA preparation and Southern blot analysis DNA was prepared from cells in log phrase by lysis of the cells in 0.3 M lithium acetate, 1 mM EDTA, 10mM Tris pH 8.0, 2.0% lithium dodecyl sulphate. The lysate was then subjected to three phenol-chloroform extractions and DNA precipitated from the final aqueous phase with 0.2M sodium acetate and 95% ethanol. Ten micrograms of DNA were completely digested with Bgl II at 37°C and size fractionated in 0.8% agarose gel. The DNA was denatured and transferred to nylon filter according to Southern (Southern, 1975) . Filters were treated with UV light for 2-5min. The oligolabelled mdrl cDNA probe at a concentration of 106 counts min-1 ml-I was hybridised to the filter as described above. Filters were washed free of unhybridised probe with 0.1 x SSC, 0.1% SDS at 65°C and autoradiographed.
Results
Immunodetection of P-glycoprotein Western blot analysis of microsomal membranes from H69P and LX4 followed by immunoblotting with MoAb C219 demonstrated the presence of P-glycoprotein in the CHRC5 cell line and LX4 subline but not in H69P (Figure 1) . A trace amount of P-glycoprotein was detected with this antibody in AUXBI as previously reported by others .
Detection of P-glycoprotein mRNA The hybridisation pattern of the mdrl probe to RNA from the cell lines H69P and LX4 is shown in Figure 2a . The probe hybridised to RNA from LX4 only. The same filter as was used for the mdrl probe was also probed for the presence of actin mRNA with a plasmid probe to confirm that the H69P cell line track contained approximately the same amount of total RNA as the LX4 track. Figure 2b indicates that the actin probe hybridised to RNA in both tracks and confirms that the lack of signal with the mdrl probe in the lane containing H69P RNA is due to undetectable levels of mrdl RNA in the parent line. P-glycoprotein gene amplification Southern filter hybridisation analysis of P-glycoprotein gene amplification in H69P and LX4 is shown in Figure 3 . Amplification of the P-glycoprotein gene is observed in LX4 only.
Discussion
Good evidence supports an aetiological role for Pglycoprotein in MDR in almost all cell lines studied. However, amplification and expression of the P-glycoprotein gene in LX4 is particularly notable in view of an earlier report (Mirski et al., 1987; Trent et al., 1988 ) which failed to demonstrate amplification, rearrangement or expression of the P-glycoprotein gene in a similar MDR variant of NCI-H69, designated H69/AR. This MDR subline was also selected for resistance to ADM, exhibits approximately the same degree of resistance to ADM as LX4, and like LX4 is cross-resistant to vincristine, colchicine and etoposide, but not to bleomycin. While the pCHPl probe was used to detect P-glycoprotein gene amplification and expression in H69/AR and mdrl specific cDNA probe (pHDR105) was used in the present study, both investigations utilised the monoclonal antibody C219, which detects a highly conserved determinant of P-glycoprotein. This antibody, while reacting with LX4, failed to detect Pglycoprotein in H69/AR (Mirski et al., 1987; Trent et al., 1988) . Hence, our findings and those previously reported for H69/AR (Mirksi et al., 1987; Trent et al., 1988) indicate that a single selecting agent can generate MDR variants from a single cell line, which have similar degrees of MDR, but which may or may not express P-glycoprotein. The nature of the cellular changes reponsible for the MDR phenotype in cells not expressing P-glycoprotein (i.e. H69/AR) remain to be elucidated. However, it is apparent that the NCI-H69 cell line has at least two alternative biochemical pathways which lead to MDR: one involving P-glycoprotein, the other not. This is further supported by the observed differences in the efficacy of verapamil (VRP) to overcome MDR in H69/AR and LX4. Only drug resistance associated with Pglycoprotein has been shown to be susceptible to reversal by VRP and for LX4 a clear dose-dependent enhancement of ADM sensitivity by VRP has been demonstrated . However, for H69/AR, verapamil enhanced ADM cytotoxicity only slightly and the effect was not dose-dependent (Cole et al., 1989 ). NCI-H69 shows a LX4 H69P a b heterogenous cytology, being a mixture of intermediate and large cell types (A.F. Gazdar, personal communication) . Whether the expression of alternative mechanisms of MDR by NCI-H69 reflects the intrinsic properties of different cell types within the line, or whether a single cell type possesses multiple mechanisms of drug resistance, remains to be elucidated.
The findings of the present study show that the MDR SCLC tumour cells in vitro are able to elaborate a MDR phenotype involving P-glycoprotein and raise the possibility that P-glycoprotein hyperexpression is a clinically relevant component of MDR in some SCLC tumours. However, to date studies of mdrl gene expression in SCLC cell lines from drug-treated patients have found no evidence that this is the case (A.F. Gazdar, personal communication).
